ERBB2 and endometrial serous adenocarcinoma: She was then enrolled in a clinical trial (NCT01367002), “Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma).” She was randomized to the trial arm without trastuzumab and completed six cycles of carboplatin/paclitaxel chemotherapy.